Iratumumab

Iratumumab^?
Therapeutic monoclonal antibody
Source	Human
Target	CD30
Identifiers
CAS number	640735-09-7
ATC code	?
PubChem	?
Chemical data
Formula	C₆₃₅₈H₉₈₃₀N₁₆₈₂O₁₉₉₂S₃₈
Mol. mass	170 kD
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases, or of relapsed refractory CD30-positive lymphoma including Hodgkin's disease.^[1]

This drug was developed by Medarex, Inc.

References

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

v • d • e Human monoclonal antibodies ("-u-")

"-limu-" (immune system)	immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab

"-kinu-" (interleukin as target)	Canakinumab^†, Ustekinumab

"-tumu-" (cancer immunotherapy)	Adecatumumab, Belimumab, Cixutumumab, Conatumumab, Figitumumab, Iratumumab, Ixutumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Robatumumab, Votumumab, Zalutumumab, Zanolimumab

"-osu-" (bone)	Denosumab

"-mulu-" (musculoskeletal)	Stamulumab^†

"-fungu-" (fungal)	Efungumab

"-viru-" (viral)	Exbivirumab, Foravirumab, Libivirumab, Rafivirumab, Regavirumab, Sevirumab, Tuvirumab

"-bacu-" (bacterial)	Nebacumab, Raxibacumab

"-ciru-" (cardiovascular)	Ramucirumab

*Names under consideration by the USAN Council. ^†Undergoing clinical trials.

Why are we here?
All text is available under the terms of the GNU Free Documentation License
This page is cache of Wikipedia. History